Retrospective chart review on natalizumab: Efficacy and safety of long-term treatment with natalizumab in Japanese patients with RRMS
Phase of Trial: Phase IV
Latest Information Update: 15 Apr 2019
Price : $35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 09 Apr 2019 Status changed from active, no longer recruiting to completed.
- 27 Feb 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 04 Sep 2018 New trial record